Mexico Dimenhydrinate Market – Industry Trends and Forecast to 2029

Market Analysis and Insights : Mexico Dimenhydrinate Market

Mexico dimenhydrinate market is expected to gain significant growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyzes that the market is growing with a CAGR of 2.4% in the forecast period of 2022 to 2029 and is expected to reach USD 1,054.36 thousand by 2029. Rising incidences of motion sickness and allergies are expected to drive the growth of the Mexico dimenhydrinate market.

Dimenhydrinate is an antihistamine that is used to circumvent and cure dizziness, nausea, and vomiting caused by motion sickness in children and adults. Dimenhydrinate belongs to a group of medications called antihistamines. It works by preventing problems with body balance. Dimenhydrinate is an antihistamine that reduces the natural chemical histamine in the body. The first dose should be taken 30 minutes to one hour before traveling or beginning any activity to avoid motion sickness. The dimenhydrinate is marketed as dramamine, draminate and gravol. These trade forms of dimenhydrinate are used as over-the-counter medication. Sometimes, dimenhydrinate is also used to cure Meniere's disease (a condition in the inner ear that causes extreme dizziness, loss of balance, and loss of hearing) and other inner ear problems.

The rising prevalence of nausea, vomiting, and allergies among the Mexican population may drive the Mexico dimenhydrinate market growth. Adverse effects associated with dimenhydrinate drugs can hinder the growth of the market. Awareness of use as OTC products can create opportunities for boosting the market's demand. The use of novel therapies for treating nausea can challenge the Mexico dimenhydrinate market growth.

The Mexico dimenhydrinate market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief; our team will help you create a revenue impact solution to achieve your desired goal.

Mexico Dimenhydrinate Market Scope and Market Size

The Mexico dimenhydrinate market is categorized into seven segments based on prescription type, application, route of administration, dosage form, product type, age, and distribution channel.

• On the basis of prescription type, the Mexico dimenhydrinate market is segmented into over-the-counter (OTC), and prescription drugs. In 2022, the over-the-counter (OTC) segment is expected to dominate the market since there are no specific laws for the use of OTC medications and the ability to invest in medium-scale companies in Mexico, which manufacture and supply dimenhydrinate. The brands available for our market-focused product in Mexico are OTC drugs.
• On the basis of application, the Mexico dimenhydrinate market is segmented into nausea, vomiting, dizziness, insomnia, allergies, and others. In 2022, the nausea segment is expected to dominate the Mexico dimenhydrinate market due to the rise in the geriatric population in Mexico suffering from motion sickness and increased awareness of treatment of motion sickness.
• On the basis of route of administration, the Mexico dimenhydrinate market is segmented into oral and parenteral. In 2022, the oral segment is expected to dominate the Mexico dimenhydrinate market as most of the drugs offered in the market are oral tablets due to their ease of absorption and availability.
• On the basis of dosage form, the Mexico dimenhydrinate market is segmented into tablets, chewables, syrup, injections, and others. In 2022, the tablets segment is expected to dominate the Mexico dimenhydrinate market since it is widely available and easy to absorb.
• On the basis of product type, the Mexico dimenhydrinate market is segmented into branded and generic. In 2022, the branded segment is expected to dominate the Mexico dimenhydrinate market, as most of the branded drugs offered by the companies are originally submitted by the Food and Drug Administration (FDA) and Federal Commission for the Protection against Sanitary Risk (COFEPRIS) and are highly used by consumers.
• On the basis of age group, the Mexico dimenhydrinate market is segmented into adult, geriatric, and child. In 2022, the adult segment is expected to dominate the Mexico dimenhydrinate market due to a rise in cases of nausea and dizziness cases among adults.
• On the basis of distribution channel, the Mexico dimenhydrinate market is segmented into store based retail and online based retail. In 2022, the store based retail segment is expected to dominate the Mexico dimenhydrinate market due to increased interaction with certified prescribers and health professionals for the use of anti-depressants and guaranteed payment.

Growing strategic activities by major market players to enhance awareness of dimenhydrinate to boost the market growth

The Mexico dimenhydrinate market also provides detailed market analysis for every country's growth in a particular market. Additionally, it provides detailed information regarding the market players' strategy and geographical presence. The data is available for the historical period 2011 to 2020.

Competitive Landscape and Mexico Dimenhydrinate Market Share Analysis

The Mexico dimenhydrinate market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies' focus related to Mexico Dimenhydrinate market

Some of the major players operating in the Mexico dimenhydrinate market are Johnson & Johnson SA de CV, Prestige Consumer Healthcare Inc., and CINFA LABORATORIES (a subsidiary of Mundipharma), among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many contracts and agreements are also initiated by the companies worldwide, which are further accelerating the Mexico dimenhydrinate market growth.

For instance,

• In July 2021, Prestige Consumer Healthcare announced that it had completed the acquisition of TheraTears and other over-the-counter consumer brands. This is expected to increase the company's manufacturing capacity in the U.S. and help in revenue generation.

SKU-67782